InBody Co.,Ltd (KOSDAQ:041830)
South Korea
· Delayed Price · Currency is KRW 22,250
+50 (0.22%)
Apr 1, 2025, 3:30 PM KST
InBody Co.,Ltd Revenue
In the year 2024, InBody Co.,Ltd had annual revenue of 204.46B KRW with 20.03% growth. InBody Co.,Ltd had revenue of 55.07B in the quarter ending December 31, 2024, with 31.40% growth.
Revenue
204.46B
Revenue Growth
+20.03%
P/S Ratio
1.41
Revenue / Employee
655.34M
Employees
312
Market Cap
281.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 204.46B | 34.11B | 20.03% |
| Dec 31, 2023 | 170.35B | 10.35B | 6.47% |
| Dec 31, 2022 | 160.00B | 22.17B | 16.08% |
| Dec 31, 2021 | 137.84B | 30.71B | 28.67% |
| Dec 31, 2020 | 107.12B | -9.94B | -8.49% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |